Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00529100
• Other study ID #: 10259
• Secondary ID: H3E-CA-JMHU
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: September 12, 2007
• Last updated: July 3, 2013
• Start date: December 2005
• Est. completion date: September 2012

Study information

• Verified date: July 2013
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.

Other known NCT identifiers

• NCT00470730

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: September 2012
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Some of the requirements to be in this study are:

• Patient must be at least 18 years old.

• Patient must have been diagnosed with non-small cell lung cancer.

• Patient must be able to visit the doctor's office once a week.

• Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.

• Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.

Exclusion Criteria:

Patients cannot participate in this study for any of the following reasons:

• Patient has previously had chemotherapy.

• Patient has previously had thoracic radiation therapy.

• Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry.

• Female patient is pregnant or breast-feeding.

• Patient is unsuitable to participate in the study in the opinion of the investigator.

• Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• Pemetrexed Phase 1
300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
• Cisplatin Phase 1
Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.

Procedure:
• Radiation Therapy
Phases 1 and 2: 61-65 Gy in 33-35 fractions

Drug:
• Pemetrexed Phase 2
Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
• Cisplatin Phase 2
Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.

Locations

Country	Name	City	State
Canada	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Edmonton	Alberta
Canada	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Hamilton	Ontario
Canada	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Ottawa	Ontario
Canada	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy	Recommended Phase 2 MTD was highest dose at which no more than 1 of 6 participants experienced dose level toxicity (DLT). DLT=(1) Grade 3/4 dysphagia/esophagitis, leukopenia, thrombocytopenia, febrile neutropenia, fatigue/malaise, pneumonitis, dermatitis, persistent elevation of bilirubin/alkaline phosphatase/aspartate aminotransferase only if resulting in delay of radiotherapy >1 week, delay of pemetrexed/cisplatin Cycle 2 >2 weeks, or delay of pemetrexed/cisplatin Cycle 3 past 5 weeks after radiotherapy; (2) other Grade 3 or 4 toxicity possibly related to concurrent treatment administration.	Baseline to measured progressive disease (PD; up to 1 year)	Yes
Primary	Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year	OS was defined as the time from date of enrollment to death due to any cause.	Baseline to date of death from any cause (up to 1 year)	Yes
Secondary	Phase 1: Number of Participants With Adverse Events (AE; Toxicity)	A listing of AEs is located in the Reported Adverse Event module.	Baseline to measured PD (up to 1 year)	Yes
Secondary	Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years	OS was defined as the time from date of enrollment to death due to any cause.	Baseline and 2 years and 3 years	Yes
Secondary	Phase 2: Time to Progressive Disease (PD)	Time to PD was defined as the time from study enrollment to the first date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions. Time to PD was censored at the date of death if death was due to other cause. For participants not known to have died as of the data cut-off date and who did not have PD, time to PD was censored at the last progression-free disease assessment. For participants who received subsequent cancer therapy (after discontinuation from the study therapy) before PD, time to PD was censored at the date of subsequent cancer therapy initiation.	Baseline to measured PD (up to 3 years)	No
Secondary	Phase 2: Percentage of Participants With Progression Free Survival (PFS)	The percentage of participants not known to have died as of the data cut-off date or last contact and who did not have PD.	Baseline and 1 year and 2 years and 3 years	No
Secondary	Progression Free Survival (PFS)	PFS was defined as the period from study entry until PD, death, or date of last contact. For participants not known to have died as of the data cut-off date and who did not have PD, the PFS date was censored at the last contact date (contacts considered in the determination of last progression free disease assessment).	Baseline to measured PD (up to 36 months)	No
Secondary	Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)	Response using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Objective response rate (%)=number of objective responders divided by the number of participants with measurable disease * 100, where objective responders are those participants who have met criteria either for CR or PR.	Baseline to measured PD (up to 3 years)	No
Secondary	Phase 2: Site of Progressive Disease (PD)	Summarized participants with local (progression within the sites of initial disease)/regional (disease progression adjacent to but not within the site of initial disease at the start of treatment), distant (disease progression that is blood borne to other parts of the body, including outside the chest or involving the contralateral lung), and local + distant sites of disease. Objective PD is defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions.	Baseline to measured PD (up to 3 years)	No

External Links

•   Lilly Clinical Trial Registry